Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
errenatomeran
- Development stage
- Unknown
- Lead developer
- Daiichi Sankyo
- Modality
- mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems, Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
Errenatomeran (DS-5670) is a monovalent mRNA-based vaccine developed by Daiichi Sankyo for the prevention of COVID-19 caused by the SARS-CoV-2 Omicron XBB.1.5 variant. Utilizing a proprietary lipid nanoparticle (LNP) delivery system, the vaccine delivers mRNA encoding the full-length spike protein of the XBB.1.5 lineage into host cells. Once translated, the spike protein acts as an antigen, triggering the host's immune system to produce neutralizing antibodies and activate T-cell responses specific to the Omicron variant. This vaccine represents the first mRNA COVID-19 vaccine developed and manufactured domestically in Japan to receive regulatory approval. It was approved by Japan's Ministry of Health, Labour and Welfare (MHLW) in November 2023 for use as a booster dose in individuals aged 12 years and older.
- Brand names
- Daichirona
- Other names
- Daiichi Sankyo mRNA COVID-19 vaccine (Omicron XBB.1.5, monovalent)DS-5670bDS5670bDS 5670b
02
Targets
SARS-CoV-2 spike
Beyond the preview
Go deeper on errenatomeran.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on errenatomeran.